96 Tests PN: B211264


45x Ab-conjugated beads (S4P10 - Mouse OPG Ab-bead). PN: B211264A. One vial containing 100 µL of anti-mouse OPG conjugated to AimPlex Bead S4P10.

25x Biotin-detection Ab (Mouse OPG Biotin-dAb). PN: B211264B. One vial containing 100 µL of biotinylated anti-mouse OPG.

Lyophilized Standard Mix - Mouse Group 4 Panel B, 11-Plex. PN: MG4011B. One vial containing lyophilized recombinant 6CKine, Activin A, BDNF, BLC, BRAK, MDC, MIP-1γ, MIP-3β, OPG, TARC, and TIMP-1.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human Mouse OPG/Osteoprotegerin/TNFRSF11B. Can be multiplexed with other analytes in Mouse Group 4. To be used in conjunction with the AimPlex Mouse/Rat Basic Kit (PN: P200201) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage: 2-8 C in the dark

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only. Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 20 pg/mL

  • Quantitation range:

  • LLOQ: < 40 pg/mL

  • ULOQ: > 10,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Mouse Group 4: Negligible

  • Sample volume: 15 µL/test


Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor (OCIF), or tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a cytokine receptor, and a member of the tumor necrosis factor (TNF) receptor superfamily. Osteoprotegerin is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). OPG can reduce the production of osteoclasts by inhibiting the differentiation of osteoclast precursors.  Elevated OPG levels has been reported in heart diseases in placebo effect serum responses in IBS patients and in severe mental disorders. Mutations in TNFRSF11B are associated with osteoarthritis. It has been found that osteoprotegerin is expressed on mesenchymal stem cells, which mediates their suppressive effect on osteoclastogenesis. It has been hypothesized that osteoprotegerin may be a link between bone and cardiovascular disease. It has been particularly related to the increase in cardiovascular risk in patients suffering from diabetes. Diseases associated with OPG/TNFRSF11B include Paget disease, juvenile and bone cancer.


  1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (April 1997). "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density". Cell 89 (2): 309–19. doi:10.1016/S0092-8674(00)80209-3. PMID 9108485.

  2. Schoppet M, Preissner KT, Hofbauer LC (April 2002). "RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function". Arterioscler. Thromb. Vasc. Biol. 22 (4): 549–53. doi:10.1161/01.ATV.0000012303.37971.DA. PMID 11950689.

  3. Hope S, Melle I, Aukrust P, Agartz I, Lorentzen S, Steen NE, Djurovic S, Ueland T, Andreassen OA (September 2010). "Osteoprotegerin levels in patients with severe mental disorders". J Psychiatry Neurosci 35 (5): 304–10. doi:10.1503/jpn.090088. PMC 2928283. PMID 20569643.